Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Phosphorylation Turns a Tumor Suppressor into a Promoter of Cancer Development

By LabMedica International staff writers
Posted on 03 Aug 2016
Cancer researchers have determined the molecular mechanism by which a modification to the protein encoded by the RUNX3 gene turns a tumor suppressor into a promoter of cancer development and progression.

There are three mammalian RUNX genes, RUNX1, RUNX2, and RUNX3, all of which are associated with oncogenic activities. More...
While RUNX3 is a key tumor suppressor in many tissue types such as gastric, colon and bladder, it promotes oncogenesis in ovarian and skin cancers. The RUNX3 gene encodes a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence found in a number of enhancers and promoters and can either activate or suppress transcription. It usually functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer.

Investigators at the National University of Singapore (Singapore) reported in the May 23, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that the phosphorylation of the threonine 173 (T173) residue within the Runt domain of RUNX3 disrupted RUNX DNA binding activity during mitotic entry to facilitate the recruitment of RUNX proteins to mitotic structures. Moreover, knockdown of RUNX3 delayed mitotic entry.

Phosphorylation of the RUNX3 protein was found to be carried out by the Aurora kinase enzyme, which is present in unusually high levels in some cancers. Phosphorylation prevented the binding of RUNX3 to DNA, resulting in RUNX3 relocating to centrosomes where it promoted uncontrolled cell division.

”Unlike other modifications which stem from changes to the RUNX3 DNA itself or how DNA is read, phosphorylation does not accompany any changes in the DNA and is hence undetectable at the genetic level. Given that modifications such as phosphorylation are likely to be impermanent and reversible, the clinical implications are far ranging. Moving forward, the team is looking into ways to assess the feasibility of enhancing RUNX tumor suppression or inhibiting RUNX mitotic function to kill rapidly proliferating cancer cells,” said senior author Dr. Yoshiaki Ito, professor of medical oncology at the National University of Singapore.

Related Links:
National University of Singapore



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.